Gabriel Cabot

4.7k total citations
57 papers, 3.1k citations indexed

About

Gabriel Cabot is a scholar working on Molecular Medicine, Molecular Biology and Pharmacology. According to data from OpenAlex, Gabriel Cabot has authored 57 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Medicine, 35 papers in Molecular Biology and 19 papers in Pharmacology. Recurrent topics in Gabriel Cabot's work include Antibiotic Resistance in Bacteria (50 papers), Bacterial biofilms and quorum sensing (30 papers) and Antibiotics Pharmacokinetics and Efficacy (19 papers). Gabriel Cabot is often cited by papers focused on Antibiotic Resistance in Bacteria (50 papers), Bacterial biofilms and quorum sensing (30 papers) and Antibiotics Pharmacokinetics and Efficacy (19 papers). Gabriel Cabot collaborates with scholars based in Spain, Sweden and India. Gabriel Cabot's co-authors include Antonio Oliver, Carlos Juan, Bartolomé Moyá, Laura Zamorano, Antonio Oliver, Xavier Mulet, Carla López-Causapé, Alain A. Ocampo-Sosa, Carmen Peña and Luis Martínez‐Martínez and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Clinical Microbiology.

In The Last Decade

Gabriel Cabot

57 papers receiving 3.0k citations

Peers

Countries citing papers authored by Gabriel Cabot

Since Specialization

Citations

This map shows the geographic impact of Gabriel Cabot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Cabot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Cabot more than expected).

Fields of papers citing papers by Gabriel Cabot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Cabot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Cabot. The network helps show where Gabriel Cabot may publish in the future.

Co-authorship network of co-authors of Gabriel Cabot

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Cabot. A scholar is included among the top collaborators of Gabriel Cabot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Cabot. Gabriel Cabot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Differential contribution of PBP occupancy and efflux on the effectiveness of β-lactams at their target site in clinical isolates of Neisseria gonorrhoeae 2024 ·PLoS Pathogens ·(unknown), (unknown), (unknown), (unknown), Gabriel Cabot, María A. Gomis-Font, Antonio Oliver, Bartolomé Moyá	1
2	Transferable AmpCs in Klebsiella pneumoniae : interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications 2024 ·Antimicrobial Agents and Chemotherapy ·Isabel M. Barceló, (unknown), Gabriel Cabot, (unknown), Elena Jordana‐Lluch, (unknown), Gabriel Torrens, Estrella Rojo‐Molinero, Laura Zamorano, Astrid Pérez, Antonio Oliver, Carlos Juan	2
3	Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa 2022 ·Journal of Antimicrobial Chemotherapy ·Cristina Lasarte-Monterrubio, Pablo A. Fraile-Ribot, Juan Carlos Vázquez-Ucha, Gabriel Cabot, (unknown), (unknown), Soraya Rumbo‐Feal, Fátima Galán‐Sánchez, Alejandro Beceiro, Jorge Arca-Suárez, Antonio Oliver, Germán Bou	42
4	In vitroevolution of cefepime/zidebactam (WCK 5222) resistance inPseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact onin vivoefficacy 2021 ·Journal of Antimicrobial Chemotherapy ·Isabel M. Barceló, Gabriel Cabot, (unknown), Prashant Joshi, (unknown), Hariharan Periasamy, Sara Cortés-Lara, Laura Zamorano, Irina Sánchez-Diener, Bartolomé Moyá, Sachin Bhagwat, Mahesh Patel, Antonio Oliver	23
5	Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones 2021 ·Journal of Antimicrobial Chemotherapy ·María A. Gomis-Font, Gabriel Cabot, (unknown), Laura Zamorano, Carlos Juan, Bartolomé Moyá, Antonio Oliver	21
6	Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning‐enabled molecular diagnostics 2020 ·EMBO Molecular Medicine ·Ariane Khaledi, Aaron Weimann, Monika Schniederjans, Ehsaneddin Asgari, (unknown), Antonio Oliver, Gabriel Cabot, Axel Kola, Petra Gastmeier, Michael Hogardt, Daniel E Jonas, (unknown), Andreas Bremges, Alice C. McHardy, Susanne Häußler	127
7	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa 2020 ·Journal of Antimicrobial Chemotherapy ·María A. Gomis-Font, Gabriel Cabot, Irina Sánchez-Diener, Pablo A. Fraile-Ribot, Carlos Juan, Bartolomé Moyá, Laura Zamorano, Antonio Oliver	37
8	Molecular mechanisms driving thein vivodevelopment of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDRPseudomonas aeruginosainfections 2020 ·Journal of Antimicrobial Chemotherapy ·Jorge Arca-Suárez, Cristina Lasarte-Monterrubio, (unknown), Gabriel Cabot, Juan Carlos Vázquez-Ucha, Manuel Rodríguez‐Iglesias, Fátima Galán‐Sánchez, Alejandro Beceiro, Concepción González‐Bello, Antonio Oliver, Germán Bou	49
9	Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection 2020 ·Journal of Antimicrobial Chemotherapy ·Jorge Arca-Suárez, Juan Carlos Vázquez-Ucha, Pablo A. Fraile-Ribot, Emilio Lence, Gabriel Cabot, Marta Martínez-Guitián, Cristina Lasarte-Monterrubio, Manuel Rodríguez‐Iglesias, Alejandro Beceiro, Concepción González‐Bello, Fátima Galán‐Sánchez, Antonio Oliver, Germán Bou	35
10	Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa 2020 ·Journal of Antimicrobial Chemotherapy ·Bartolomé Moyá, Sachin Bhagwat, Gabriel Cabot, Germán Bou, Mahesh Patel, Antonio Oliver	40
11	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of Pseudomonas aeruginosa 2020 ·European Journal of Clinical Microbiology & Infectious Diseases ·Felipe Fernández-Cuenca, Lorena López‐Cerero, Gabriel Cabot, Antonio Oliver, (unknown), Esther Recacha, (unknown), Jesús Rodríguez‐Baño, Álvaro Pascual	10
12	In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae 2019 ·Antimicrobial Agents and Chemotherapy ·Bartolomé Moyá, Isabel M. Barceló, Gabriel Cabot, Gabriel Torrens, (unknown), Prashant Joshi, (unknown), (unknown), Hariharan Periasamy, Sachin Bhagwat, Mahesh Patel, Germán Bou, Antonio Oliver	40
13	Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections 2019 ·Frontiers in Microbiology ·Gabriel Torrens, (unknown), (unknown), (unknown), Gabriel Cabot, Carla López-Causapé, Estrella Rojo‐Molinero, Antonio Oliver, Carlos Juan	14
14	The Versatile Mutational Resistome of Pseudomonas aeruginosa 2018 ·Frontiers in Microbiology ·Carla López-Causapé, Gabriel Cabot, Ester del Barrio-Tofiño, Antonio Oliver	174
15	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system 2017 ·PLoS ONE ·Gabriel Torrens, (unknown), Bartolomé Moyá, (unknown), Laura Zamorano, Gabriel Cabot, Jesús Blázquez, Juan A. Ayala, Antonio Oliver, Carlos Juan	30
16	Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone 2017 ·Scientific Reports ·Carla López-Causapé, Lea M. Sommer, Gabriel Cabot, (unknown), Alain A. Ocampo-Sosa, Helle Krogh Johansen, Joan Figuerola, Rafael Cantón, Timothy J. Kidd, Søren Molin, Antonio Oliver	109
17	Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies 2016 ·International Journal of Antimicrobial Agents ·Sílvia Gómez-Zorrilla, Carlos Juan, Gabriel Cabot, Mariana Camoez, Fé Tubau, Antonio Oliver, M.Á. Domínguez, Javier Ariza, Carmen Peña	33
18	Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model 2016 ·International Journal of Antimicrobial Agents ·Sílvia Gómez-Zorrilla, Laura Calatayud, Carlos Juan, Gabriel Cabot, Fé Tubau, Antonio Oliver, M.Á. Domínguez, Javier Ariza, Carmen Peña	11
19	N-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in Pseudomonas aeruginosa by an OprD-Mediated Mechanism 2015 ·Antimicrobial Agents and Chemotherapy ·Jerónimo Rodríguez-Beltrán, Gabriel Cabot, (unknown), Coloma Costas, Germán Bou, Antonio Oliver, Jesús Blázquez	16
20	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem 2011 ·Journal of Antimicrobial Chemotherapy ·Elena Riera, Gabriel Cabot, Xavier Mulet, María García-Castillo, Rosa del Campo, Carlos Juan, Rafael Cantón, Antonio Oliver	130

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact